Lekap

Sildenafil, the active ingredient in Lekap, is a phosphodiesterase type 5 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of erectile dysfunction in men and for pulmonary arterial hypertension, improving blood flow in the relevant vascular beds.

GNH USA supplies Lekap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. Customers benefit from consistent product availability and comprehensive regulatory support.

Sildenafil acts on the phosphodiesterase type 5 pathway, addressing conditions related to vascular smooth‑muscle tone and blood flow regulation.

Erectile dysfunction: improves the ability to achieve and maintain an erection sufficient for satisfactory sexual activity by enhancing blood flow to the corpus cavernosum. Pulmonary arterial hypertension: enhances exercise capacity and reduces pulmonary arterial pressure by promoting vasodilation in the pulmonary vasculature, thereby improving hemodynamics. Male sexual dysfunction: supports overall sexual performance in men with vascular‑related erectile issues by increasing penile blood flow.

Sildenafil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache. - Flushing: warmth and redness of the face or upper chest. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: stuffy nose. - Back pain: aching discomfort in the lower back. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours requiring medical attention. - Sudden vision loss: abrupt loss of vision in one or both eyes, possibly indicating non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: rapid decrease or loss of hearing, sometimes accompanied by tinnitus. - Myocardial infarction: heart attack symptoms such as chest pain or pressure. - Stroke: neurological deficits including sudden weakness, speech difficulty, or facial droop.

Before prescribing Lekap, clinicians should consider several safety factors.

- Cardiovascular assessment: evaluate recent heart conditions before prescribing. - Concomitant nitrate use: avoid co‑administration due to risk of severe hypotension. - Visual disturbances: monitor patients with retinal disorders. - Hearing changes: advise patients to report sudden hearing loss. - Dosage adjustment: consider renal or hepatic impairment when determining dose. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct light.

Sildenafil can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): may cause profound hypotension. - Nitric oxide donors (e.g., amyl nitrite): risk of severe blood pressure drop. - Riociguat: combined vasodilatory effect can be dangerous.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., doxazosin): may cause additive blood pressure lowering. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.